Have you had a stroke, a heart attack, or have poor circulation?
Participating in this clinical study has the potential to improve future treatment options for people living with obesity and cardiovascular disease.
REDEFINE 3 is looking at the combination of cagrilinitide and semaglutide (CagriSema), which is being investigated for the potential to help treat obesity and impact cardiovascular risk factors. REDEFINE 3 is needed to help us understand the effect and safety of CagriSema on the cardiovascular system.
Who can participate?
You may be eligible to participate in this clinical study if you fulfil the following:
- be 55 years or older
- have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
arterial disease) - have a BMI ≥ 30 kg/m2
- have type 2 diabetes.
This study is being run in Victoria (Prahran).
Apply to participate in this study
Benefits
- Expert medical care and education from a dedicated team of doctors and nurses.
- Study-related care, including regular health check-ups.
- Helping others by contributing to medical research.
If you are interested in participating or would like further information, please contact the REDEFINE 3 study team:
Prasad Senevirathna
Clinical Research Coordinator
T: (03) 8532 1305
E: prasad.senevirathna@baker.edu.au